VBL Therapeutics (Nasdaq: VBLT), a clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that it has been selected for €17.5 million of blended funding by the European Innovation Council (EIC) Accelerator. The funding is comprised of a €2.5 million grant and an additional €15 million direct equity investment by the EIC.

VBL is among only 9% of companies across industries selected by the EIC Accelerator Funds to be used for clinical development, CMC, and pre-commercialization activities for ofra-vec (VB-111)  TEL AVIV, Israel and NEW YORK, Dec.  20, 2021  (GLOBE NEWSWIRE) --

Vbl Therapeutics Selected For €17.5 Million Of Funding From Horizon Europe Eic Accelerator Program

Description

Company Information

Vbl Therapeutics Selected For €17.5 Million Of Funding From Horizon Europe Eic Accelerator Program

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Company Information